Lyell Immunopharma (NASDAQ:LYEL - Get Free Report ) 's stock had its "buy" rating restated by investment analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $6.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 136.22% from the stock's previous close.
Get Lyell Immunopharma alerts:
Sign Up
Lyell Immunopharma Stock Performance LYEL remained flat at $2.54 during midday trading on Tuesday. 926,958 shares of the company traded hands, compared to its average volume of 968,357. The stock has a market capitalization of $647.55 million, a P/E ratio of -2.68 and a beta of -0.54. The company's 50 day moving average price is $2.34 and its two-hundred day moving average price is $2.08. Lyell Immunopharma has a 52-week low of $1.32 and a 52-week high of $3.97.
Lyell Immunopharma (NASDAQ:LYEL - Get Free Report ) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.21) by $0.01. The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $4.96 million. Lyell Immunopharma had a negative net margin of 180,486.14% and a negative return on equity of 32.67%. On average, equities analysts forecast that Lyell Immunopharma will post -0.84 earnings per share for the current fiscal year.
Institutional Inflows and Outflows Institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. raised its position in shares of Lyell Immunopharma by 13.2% in the third quarter. Principal Financial Group Inc. now owns 68,080 shares of the company's stock valued at $100,000 after purchasing an additional 7,915 shares during the period. Profund Advisors LLC raised its holdings in Lyell Immunopharma by 20.0% in the 3rd quarter. Profund Advisors LLC now owns 73,442 shares of the company's stock worth $108,000 after acquiring an additional 12,225 shares during the period. Public Employees Retirement System of Ohio lifted its position in Lyell Immunopharma by 109.7% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 27,203 shares of the company's stock worth $40,000 after acquiring an additional 14,229 shares during the last quarter. Vanguard Personalized Indexing Management LLC acquired a new position in Lyell Immunopharma during the 4th quarter worth $31,000. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in Lyell Immunopharma by 67.7% during the first quarter. China Universal Asset Management Co. Ltd. now owns 48,855 shares of the company's stock valued at $109,000 after acquiring an additional 19,718 shares during the period. 66.05% of the stock is owned by institutional investors.
Lyell Immunopharma Company Profile (
Get Free Report )
Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.
Read More Before you consider Lyell Immunopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.
While Lyell Immunopharma currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
